Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

29-Jul-2020 - Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe. Sandoz CEO Richard Saynor said: “This plan is a great ...

Novartis announces change in Sandoz leadership

14-Mar-2019 - Novartis announced that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to ...

Sandoz initiates two more Phase III biosimilar trials

20-Jan-2012 - Sandoz announced that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).The filgrastim study is to evaluate the efficacy and safety of ...

Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab

14-Jan-2011 - Sandoz announced that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera®), a monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis.The phase II study in patients suffering from rheumatoid ...

Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox

27-Jul-2010 - Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®, in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA). According to IMS data enoxaparin sodium injection is the best-selling hospital ...

Sandoz completes acquisition of EBEWE Pharma, improving global patient access to affordable injectable cancer medicines

Sandoz to focus on quick and seamless integration for customers and employees

25-Sep-2009 - Sandoz announced that it has completed its USD 1.3 billion acquisition of EBEWE Pharma's specialty generic injectables business, paving the way for the creation of a global center of excellence in generic oncology injectables. "We are delighted to combine EBEWE Pharma's portfolio and pipeline of ...

Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex

08-Sep-2009 - Orion Corporation and Hospira, Inc. filed together a patent infringement lawsuit in the United States to enforce Orion's U.S. Patent No.4,910,214 and Orion's and Hospira's commonly owned U.S. Patent No. 6,716,867 against Sandoz International Gmbh and Sandoz Inc. Sandoz Inc. seeks authorisation ...

Sandoz receives approval for first-ever Japanese biosimilar

Sandoz receives approval for first-ever Japanese biosimilar, recombinant human growth hormone somatropin, further reinforcing global pioneer position in field

26-Jun-2009 - Sandoz has received marketing authorization for the first-ever Japanese biosimilar, recombinant human growth hormone somatropin. The Ministry of Health, Labor and Wealth (MHLW) announced the approval on June 22, barely three months after the Japanese authorities published guidelines that paved ...

Sandoz to acquire EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs

Definitive agreement to acquire EBEWE Pharma's specialty injectables business for EUR 925 million (USD 1.2 billion) in an all-cash transaction

25-May-2009 - Novartis has signed a definitive agreement to acquire the specialty generic injectables business of EBEWE Pharma, providing Sandoz - the Group's generic pharmaceuticals division - an opportunity to create a global platform for future growth while improving access for patients worldwide to many ...

LifeCycle Pharma Enters Three Distinct Strategic Collaboration Agreements With Global Pharmaceutical Companies

12-Oct-2006 - LifeCycle Pharma A/S announced that it has entered into three strategic collaboration agreements with Sandoz Inc. (an affiliate of Novartis AG), Merck Generics (a subsidiary of Merck KGaA of Darmstadt, Germany) and H. Lundbeck A/S. Sandoz and LifeCycle Pharma have entered into an exclusive ...